Literature DB >> 30450293

Extrapleural pneumonectomy: still indicated?

Andreas Domen1, Lawek Berzenji1, Jeroen M H Hendriks1, Suresh Krishan Yogeswaran1, Patrick Lauwers1, Jan P Van Meerbeeck2, Paul E Van Schil1.   

Abstract

The optimal treatment of malignant pleural mesothelioma (MPM) has not yet been established and is still under investigation. Surgery is one of the pillars in the multimodality approach with the purpose of removing as much as visible tumor as possible and to relieve symptoms. To date, two major surgical procedures are available for removal or debulking of MPM that is considered to be resectable: [extended (e)] pleurectomy/decortication (P/D) and extrapleural pneumonectomy (EPP). Historically, EPP was regarded as the only way to achieve a macroscopic complete resection. However, in the last years, there is a shift in literature towards (e)P/D as the preferred surgical procedure whenever possible as several retrospective studies and meta-analyses showed a similar or lower long-term survival and higher perioperative mortality and postoperative morbidity in patients who been treated with EPP. On the other hand, no randomized-controlled trials regarding surgical treatment with (e)P/D or EPP exist and therefore level A evidence favoring one surgical procedure is lacking. In this review we provide a nuanced and well-considered answer to the question whether EPP is still indicated in the surgical treatment of MPM.

Entities:  

Keywords:  Malignant pleural mesothelioma (MPM); extrapleural pneumonectomy (EPP); pleurectomy decortication (P/D); surgery

Year:  2018        PMID: 30450293      PMCID: PMC6204420          DOI: 10.21037/tlcr.2018.07.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN: 2218-6751


  31 in total

1.  Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure.

Authors:  Ottavio Rena; Caterina Casadio
Journal:  Lung Cancer       Date:  2012-01-11       Impact factor: 5.705

2.  The MARS feasibility trial: conclusions not supported by data.

Authors:  Walter Weder; Rolf A Stahel; Paul Baas; Urania Dafni; Marc de Perrot; Brian C McCaughan; Takashi Nakano; Harvey I Pass; Bruce W S Robinson; Valerie W Rusch; David J Sugarbaker; Nico van Zandwijk
Journal:  Lancet Oncol       Date:  2011-11       Impact factor: 41.316

Review 3.  Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.

Authors:  Emanuela Taioli; Maaike van Gerwen; Meredith Mihalopoulos; Gil Moskowitz; Bian Liu; Raja Flores
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

4.  Multimodal management of malignant pleural mesothelioma: where are we today?

Authors:  Paul E Van Schil; Isabelle Opitz; Walter Weder; Christophe De Laet; Andreas Domen; Patrick Lauwers; Jeroen M Hendriks; Jan P Van Meerbeeck
Journal:  Eur Respir J       Date:  2014-02-13       Impact factor: 16.671

5.  NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Authors:  David S Ettinger; Douglas E Wood; Wallace Akerley; Lyudmila A Bazhenova; Hossein Borghaei; David Ross Camidge; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Thomas Dilling; Michael Dobelbower; Ramaswamy Govindan; Mark Hennon; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; Neelesh Sharma; Scott J Swanson; James Stevenson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2016-07       Impact factor: 11.908

6.  Pleurectomy/decortication versus extrapleural pneumonectomy: a critical choice.

Authors:  Pier Luigi Filosso; Francesco Guerrera; Paolo Olivo Lausi; Roberto Giobbe; Paraskevas Lyberis; Enrico Ruffini; Alberto Oliaro
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 7.  Extrapleural pneumonectomy (EPP) vs. pleurectomy decortication (P/D).

Authors:  Hasan Fevzi Batirel
Journal:  Ann Transl Med       Date:  2017-06

8.  Malignant pleural mesothelioma: single-institution experience of 101 patients over a 15-year period.

Authors:  Andreas Domen; Christophe De Laet; Wies Vanderbruggen; Jan Gielis; Jeroen M H Hendriks; Patrick Lauwers; Annelies Janssens; Birgitta Hiddinga; Jan P Van Meerbeeck; Paul E Van Schil
Journal:  Acta Chir Belg       Date:  2017-06       Impact factor: 1.090

9.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

10.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Authors:  Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto
Journal:  Lancet Oncol       Date:  2011-06-30       Impact factor: 41.316

View more
  1 in total

1.  Single-Center 20-Year Experience in Surgical Treatment of Malignant Pleural Mesothelioma.

Authors:  Giuseppe Mangiameli; Edoardo Bottoni; Umberto Cariboni; Giorgio Maria Ferraroli; Emanuela Morenghi; Veronica Maria Giudici; Emanuele Voulaz; Marco Alloisio; Alberto Testori
Journal:  J Clin Med       Date:  2022-08-03       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.